[Seungkwon Kim, Edaily Reporter] Samsung Biologics has secured two new contract manufacturing (CMO) deals worth a combined 440.5 billion won ($319.6 million) with pharmaceutical companies based in Asia and Europe, the company said in a regulatory filing Monday.

The European contract is valued at 242 billion won ($175.6 million) and will run through December 2030, while the Asian contract, worth 198.5 billion won ($144 million), extends to December 2033. Specific clients and product names were not disclosed due to confidentiality agreements.

Samsung Biologics

The deals push Samsung Biologics’ total order intake for 2025 to approximately 3.25 trillion won ($2.4 billion), reaching 60% of the company’s full-year 2024 total of 5.4 trillion won in just five months. The company has announced four new contracts so far this year, spanning the U.S., Asia, and Europe.

Samsung Biologics currently counts 17 of the world’s top 20 pharmaceutical companies as clients. Since its founding, the South Korean CDMO giant has secured cumulative orders worth more than $18.2 billion, driven by its production capacity, quality performance, and proven track record.

The company recently launched its fifth plant, a 180,000-liter facility integrating best practices from its previous four plants, which brings its total capacity to 784,000 liters, the largest in the world.

Samsung Biologics also continues to lead in manufacturing quality. In 2024, the company achieved a 99% batch success rate and, as of April 2025, has received 356 manufacturing approvals from major regulatory agencies, including those in the U.S., Europe, and Japan. Approval counts are expected to rise in line with production capacity expansions, with inspection success rates remaining among the industry‘s highest.

To broaden its global reach, Samsung Biologics has actively participated in major industry events throughout the year. After attending the J.P. Morgan Healthcare Conference in January and DCAT Week in March, the company met clients and prospects at PEGS Boston in May. It is scheduled to attend the BIO International Convention in Boston this June to further strengthen its order pipeline.